Sutro Biopharma, Inc. (STRO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol STRO
- Company Sutro Biopharma, Inc.
- Price $0.88
- Changes Percentage -2.23
- Change -0.0201
- Day Low $0.88
- Day High $0.89
- Year High $5.17
- Year Low $0.52
- Market Cap $75,926,988
- Price Avg 50 EMA (D) $1.1
- Price Avg 200 EMA (D) $2.7
- Exchange NASDAQ
- Volume 3,094,877
- Average Volume 1,585,463
- Open $0.88
- Previous Close $0.9
- EPS -2.96
- PE -0.30
- Earnings Announcement 2025-05-12 10:59:00
- Shares Outstanding $84,363,320
Company brief: SUTRO BIOPHARMA, INC. (STRO )
- Healthcare
- Biotechnology
- Mr. William J. Newell J.D.
- https://www.sutrobio.com
- US
- N/A
- 09-27-2018
- US8693671021
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.